JP2010528995A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010528995A5 JP2010528995A5 JP2010509701A JP2010509701A JP2010528995A5 JP 2010528995 A5 JP2010528995 A5 JP 2010528995A5 JP 2010509701 A JP2010509701 A JP 2010509701A JP 2010509701 A JP2010509701 A JP 2010509701A JP 2010528995 A5 JP2010528995 A5 JP 2010528995A5
- Authority
- JP
- Japan
- Prior art keywords
- alk
- het
- proportions
- atoms
- pharmaceutically usable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 10
- 239000012453 solvate Substances 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- -1 1-azabicyclo [2.2.2] octanyl Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000005764 inhibitory process Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims 3
- 125000004434 sulfur atom Chemical group 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 210000003128 head Anatomy 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- FPYJSJDOHRDAMT-KQWNVCNZSA-N 1h-indole-5-sulfonamide, n-(3-chlorophenyl)-3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1h-pyrrol-2-yl]methylene]-2,3-dihydro-n-methyl-2-oxo-, (3z)- Chemical compound C=1C=C2NC(=O)\C(=C/C3=C(C(C(=O)N4CCN(C)CC4)=C(C)N3)C)C2=CC=1S(=O)(=O)N(C)C1=CC=CC(Cl)=C1 FPYJSJDOHRDAMT-KQWNVCNZSA-N 0.000 claims 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 claims 1
- 125000005049 dihydrooxadiazolyl group Chemical group O1N(NC=C1)* 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000004324 lymphatic system Anatomy 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007025718A DE102007025718A1 (de) | 2007-06-01 | 2007-06-01 | Pyridazinonderivate |
| DE102007025718.1 | 2007-06-01 | ||
| PCT/EP2008/003550 WO2008145243A1 (de) | 2007-06-01 | 2008-05-02 | Pyridazinonderivate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010528995A JP2010528995A (ja) | 2010-08-26 |
| JP2010528995A5 true JP2010528995A5 (Direct) | 2011-06-23 |
| JP5485875B2 JP5485875B2 (ja) | 2014-05-07 |
Family
ID=39671665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010509701A Expired - Fee Related JP5485875B2 (ja) | 2007-06-01 | 2008-05-02 | ピリダジノン誘導体 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8367668B2 (Direct) |
| EP (1) | EP2150539B1 (Direct) |
| JP (1) | JP5485875B2 (Direct) |
| KR (1) | KR20100027188A (Direct) |
| CN (1) | CN101679303B (Direct) |
| AR (1) | AR066770A1 (Direct) |
| AU (1) | AU2008255328B2 (Direct) |
| BR (1) | BRPI0812247A2 (Direct) |
| CA (1) | CA2688518C (Direct) |
| DE (1) | DE102007025718A1 (Direct) |
| EA (1) | EA200901601A1 (Direct) |
| ES (1) | ES2444218T3 (Direct) |
| IL (1) | IL202376A (Direct) |
| MX (1) | MX2009012708A (Direct) |
| WO (1) | WO2008145243A1 (Direct) |
| ZA (1) | ZA200909054B (Direct) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102008062826A1 (de) | 2008-12-23 | 2010-07-01 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102009003954A1 (de) * | 2009-01-07 | 2010-07-08 | Merck Patent Gmbh | Pyridazinonderivate |
| WO2010123822A1 (en) * | 2009-04-20 | 2010-10-28 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyridazine sulfonamide derivatives |
| JP2013514973A (ja) * | 2009-12-21 | 2013-05-02 | メルク・シャープ・エンド・ドーム・コーポレイション | チロシンキナーゼ阻害剤 |
| US20130315895A1 (en) | 2010-07-01 | 2013-11-28 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
| CN102731409A (zh) * | 2011-04-08 | 2012-10-17 | 中国科学院上海药物研究所 | 一类哒嗪酮类化合物，其药物组合物、制备方法及用途 |
| WO2013185284A1 (en) | 2012-06-12 | 2013-12-19 | Abbott Laboratories | Pyridinone and pyridazinone derivatives |
| WO2014031928A2 (en) * | 2012-08-24 | 2014-02-27 | Philip Jones | Heterocyclic modulators of hif activity for treatment of disease |
| HUE040025T2 (hu) | 2012-08-24 | 2019-02-28 | Univ Texas | A HIF aktivitás heterociklusos modulátorai betegség kezelésére |
| CN103664895B (zh) * | 2012-08-28 | 2018-02-27 | 中国科学院上海药物研究所 | 哒嗪酮类化合物、其制备方法、药物组合物及其用途 |
| HRP20221389T1 (hr) | 2013-10-18 | 2023-01-06 | Celgene Quanticel Research, Inc. | Inhibitori bromodomena |
| KR102116107B1 (ko) | 2013-12-30 | 2020-05-28 | 삼성디스플레이 주식회사 | 표시 장치 |
| US9988421B2 (en) | 2014-01-10 | 2018-06-05 | Cornell University | Dipeptides as inhibitors of human immunoproteasomes |
| WO2015130790A2 (en) | 2014-02-25 | 2015-09-03 | Board Of Regents, University Of Texas System | Salts of heterocyclic modulators of hif activity for treatment of disease |
| CN114796207A (zh) | 2014-08-18 | 2022-07-29 | 康奈尔大学 | 作为人免疫蛋白酶体的抑制剂的二肽模拟物 |
| WO2016091891A1 (en) | 2014-12-09 | 2016-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Human monoclonal antibodies against axl |
| WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
| ES2905008T3 (es) | 2015-10-15 | 2022-04-06 | Univ Cornell | Inhibidores de proteasomas y usos de los mismos |
| KR20180084478A (ko) | 2017-01-17 | 2018-07-25 | 김민규 | 파일 인양을 위한 굴절케이싱 및 이를 이용한 파일 인양방법 |
| EP3694605A4 (en) | 2017-10-11 | 2021-10-27 | Cornell University | PEPTIDOMIMETIC INHIBITORS OF PROTEASOME |
| PT3877376T (pt) | 2018-11-06 | 2023-09-21 | Edgewise Therapeutics Inc | Compostos de piridazinona e suas utilizações |
| DK3877052T3 (da) | 2018-11-06 | 2023-09-25 | Edgewise Therapeutics Inc | Pyridazinonforbindelser og anvendelser deraf |
| WO2020097258A1 (en) * | 2018-11-06 | 2020-05-14 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| CN114105976B (zh) * | 2020-08-28 | 2024-04-26 | 杭州邦顺制药有限公司 | 选择性rock2激酶抑制剂 |
| JP2024540485A (ja) * | 2021-11-17 | 2024-10-31 | エッジワイズ セラピューティクス， インコーポレイテッド | ピリダジノン化合物およびその使用 |
| CA3247018A1 (en) * | 2022-02-03 | 2023-08-10 | D.E. Shaw Research, Llc | PYRIDAZINONE COMPOUNDS AS TRPA1 INHIBITORS |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RO79566A2 (ro) * | 1980-05-28 | 1982-08-17 | Institutul De Cercetari Chimico-Farmaceutice,Ro | Substante din clasa 2-(3'-aril-piridazonil-1'5-metil-5-aril-(alchil)amino-tiadiazolului |
| RO79562A2 (ro) * | 1980-05-29 | 1982-08-17 | Institutul De Cercetari Chimico-Farmaceutice,Ro | Substante din clasa 3-(3'-aril-piridazonil-1'5-metil-4-aril(alchil)-5-mercapto-1,2,4-triazolului si procedeu de obtinere a acestora |
| JPS5795964A (en) | 1980-12-04 | 1982-06-15 | Morishita Seiyaku Kk | Preparation of 2-substituted-3(2h)-pyridazinone derivative |
| US4397854A (en) | 1981-05-14 | 1983-08-09 | Warner-Lambert Company | Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents |
| JPS5826802A (ja) | 1981-08-10 | 1983-02-17 | Sankyo Co Ltd | 農園芸用殺菌剤 |
| DE4134467A1 (de) * | 1991-10-18 | 1993-04-22 | Thomae Gmbh Dr K | Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| DE69131268T2 (de) * | 1990-09-21 | 1999-12-30 | Rohm And Haas Co., Philadelphia | Dihydropyridazinone und Pyridazinone als Fungizide |
| AU691673B2 (en) | 1994-11-14 | 1998-05-21 | Dow Agrosciences Llc | Pyridazinones and their use as fungicides |
| US5635494A (en) | 1995-04-21 | 1997-06-03 | Rohm And Haas Company | Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| US6184225B1 (en) | 1996-02-13 | 2001-02-06 | Zeneca Limited | Quinazoline derivatives as VEGF inhibitors |
| DE69709319T2 (de) | 1996-03-05 | 2002-08-14 | Astrazeneca Ab, Soedertaelje | 4-anilinochinazolin derivate |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| ATE319691T1 (de) * | 1997-08-22 | 2006-03-15 | Abbott Lab | Prostaglandin endoperoxyde h synthase biosynthese inhibitoren |
| ID24166A (id) | 1997-11-19 | 2000-07-13 | Kowa Co | Turunan piridazin baru dan obat-obatan yang mengandung hal yang sama sebagai ramuan efektif |
| TWI241295B (en) | 1998-03-02 | 2005-10-11 | Kowa Co | Pyridazine derivative and medicine containing the same as effect component |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| CA2406979A1 (en) | 2000-05-31 | 2001-12-06 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| BR0112224A (pt) | 2000-07-07 | 2003-06-10 | Angiogene Pharm Ltd | Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto |
| HUP0301742A3 (en) | 2000-07-07 | 2005-08-29 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use |
| GB0108102D0 (en) | 2001-03-30 | 2001-05-23 | Pfizer Ltd | Compounds |
| AUPR606401A0 (en) | 2001-07-02 | 2001-07-26 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazolopyridine compound and pharmaceutical use thereof |
| CA2462525A1 (en) | 2001-10-31 | 2003-05-08 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Type 4 phosphodiesterase inhibitors and uses thereof |
| EP1470112A1 (en) * | 2002-01-18 | 2004-10-27 | Pharmacia Corporation | Substituted pyridazinones as inhibitors of p38 |
| US7763617B2 (en) | 2005-03-07 | 2010-07-27 | Kyorin Pharmaceutical Co., Ltd. | Pyrazolopyridine-4-yl pyridazinone derivatives and addition salts thereof, and PDE inhibitors comprising the same derivatives or salts as active ingredient |
| DE102005055354A1 (de) * | 2005-11-21 | 2007-10-31 | Merck Patent Gmbh | Substituierte 5-Phenyl-3,6-dihydro-2-oxo-6H-[1,3,4]thiadiazine |
| DE102005057924A1 (de) * | 2005-12-05 | 2007-06-06 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102006037478A1 (de) * | 2006-08-10 | 2008-02-14 | Merck Patent Gmbh | 2-(Heterocyclylbenzyl)-pyridazinonderivate |
| JP2010519204A (ja) * | 2007-02-16 | 2010-06-03 | アムジエン・インコーポレーテツド | 窒素含有複素環ケトン類およびそれらのｃ−Ｍｅｔ阻害薬としての使用 |
-
2007
- 2007-06-01 DE DE102007025718A patent/DE102007025718A1/de not_active Withdrawn
-
2008
- 2008-05-02 KR KR1020097027591A patent/KR20100027188A/ko not_active Withdrawn
- 2008-05-02 MX MX2009012708A patent/MX2009012708A/es not_active Application Discontinuation
- 2008-05-02 BR BRPI0812247-4A patent/BRPI0812247A2/pt not_active IP Right Cessation
- 2008-05-02 AU AU2008255328A patent/AU2008255328B2/en not_active Ceased
- 2008-05-02 CN CN2008800179692A patent/CN101679303B/zh not_active Expired - Fee Related
- 2008-05-02 ES ES08758367.0T patent/ES2444218T3/es active Active
- 2008-05-02 EP EP08758367.0A patent/EP2150539B1/de not_active Not-in-force
- 2008-05-02 JP JP2010509701A patent/JP5485875B2/ja not_active Expired - Fee Related
- 2008-05-02 EA EA200901601A patent/EA200901601A1/ru unknown
- 2008-05-02 WO PCT/EP2008/003550 patent/WO2008145243A1/de not_active Ceased
- 2008-05-02 US US12/602,254 patent/US8367668B2/en not_active Expired - Fee Related
- 2008-05-02 CA CA2688518A patent/CA2688518C/en active Active
- 2008-05-30 AR ARP080102271A patent/AR066770A1/es unknown
-
2009
- 2009-11-26 IL IL202376A patent/IL202376A/en active IP Right Grant
- 2009-12-18 ZA ZA200909054A patent/ZA200909054B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010528995A5 (Direct) | ||
| JP2010532768A5 (Direct) | ||
| JP2011530545A5 (Direct) | ||
| HRP20120661T1 (hr) | Derivati pirimidinil piridazinona | |
| JP2015515961A5 (Direct) | ||
| JP2010529051A5 (Direct) | ||
| JP2020097596A5 (Direct) | ||
| CA2878251A1 (en) | Method of treating gastrointestinal stromal tumors | |
| JP2011510055A5 (Direct) | ||
| JP2011518202A5 (Direct) | ||
| JP5788527B2 (ja) | キナーゼ阻害剤の副作用低減剤 | |
| JP2011510028A5 (Direct) | ||
| JP2014530237A5 (Direct) | ||
| WO2012144463A1 (ja) | 腫瘍治療剤 | |
| JP2015529194A5 (Direct) | ||
| ES2945865T3 (es) | Combinación de un derivado de 6-oxo-1,6-dihidropiridazina que tiene actividad anticancerígena con un derivado de quinazolina | |
| JP2009534418A5 (Direct) | ||
| JP2010519278A5 (Direct) | ||
| WO2022005871A1 (en) | Methods of treating sars-cov-2 infection using inhibitors of lipogenesis | |
| BR112020025670A2 (pt) | Alcóxi pirazóis como ativadores de guanilato ciclase solúveis | |
| US20120213867A1 (en) | Raf inhibitors for the treatment of thyroid cancer | |
| ES2824400T3 (es) | Agente antitumoral que incluye clorhidrato de irinotecán hidratado | |
| AU2013339823B2 (en) | A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (HCC) | |
| CA2970391A1 (en) | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an egfr inhibitor | |
| JPWO2020052688A5 (Direct) |